205 related articles for article (PubMed ID: 36602979)
1. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
Yuan Y; Liu X; Cai Y; Li W
PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
[TBL] [Abstract][Full Text] [Related]
2. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
3. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
4. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
Li X; Wu S; Zhang L; Zhu J; Xu B
Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Bao Y; Zhang Z; He X; Cai L; Wang X; Li X
Curr Oncol; 2022 Aug; 29(9):6053-6067. PubMed ID: 36135045
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.
Yuan Y; Liu X; Cai Y; Li W
Syst Rev; 2022 Dec; 11(1):264. PubMed ID: 36496473
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Haddad TC; He J; O'Sullivan CC; Chen B; Northfelt D; Dueck AC; Ballman KV; Tenner KS; Linden H; Sparano JA; Hopkins JO; De Silva C; Perez EA; Haluska P; Goetz MP
Breast Cancer Res Treat; 2021 Jul; 188(2):477-487. PubMed ID: 33852121
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
[TBL] [Abstract][Full Text] [Related]
16. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
Xie XF; Zhang QY; Huang JY; Chen LP; Lan XF; Bai X; Song L; Xiong SL; Guo SJ; Du CW
Breast Cancer Res Treat; 2023 Jan; 197(1):93-101. PubMed ID: 36309908
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
18. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study.
Li F; Xu F; Li J; Wang T; Bian L; Zhang S; Jiang Z
Ann Transl Med; 2021 Jan; 9(2):103. PubMed ID: 33569405
[TBL] [Abstract][Full Text] [Related]
19. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Gavilá J; De La Haba J; Bermejo B; Rodríguez-Lescure Á; Antón A; Ciruelos E; Brunet J; Muñoz-Couselo E; Santisteban M; Rodríguez Sánchez CA; Santaballa A; Sánchez Rovira P; García Sáenz JÁ; Ruiz-Borrego M; Guerrero-Zotano AL; Huerta M; Cotes-Sanchís A; Lao Romera J; Aguirre E; Cortés J; Llombart-Cussac A
Clin Transl Oncol; 2020 Mar; 22(3):420-428. PubMed ID: 31203575
[TBL] [Abstract][Full Text] [Related]
20. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
